Arcturus Therapeutics (ARCT) Stock: Buy, Sell, or Hold?
ARCT - Arcturus Therapeutics Holdings Inc. Common Stock
$9.84
-0.89 (-8.29%)
▼
5d:
-4.84%
30d:
-30.31%
90d:
+70.83%
HOLD
LOW Confidence
Analysis Updated: Oct 23, 2026 12:00 AM ET
Earnings: Nov 09, 2026
14d
Get Alerted When ARCT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: ARCT shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: ARCT shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: ARCT is currently trading at $9.84, which is considered oversold relative to its 30-day fair value range of $11.29 to $14.94.
Technical Outlook: Technically, ARCT is in a strong uptrend. The price is currently testing key support at $9.75. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 8.3% recently.
Market Sentiment: ARCT scores 60/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $23.80 (+141.9%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, ARCT is in a strong uptrend. The price is currently testing key support at $9.75. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 8.3% recently.
Market Sentiment: ARCT scores 60/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $23.80 (+141.9%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$11.29 -
$14.94
Company Quality Score
64/100
(BUY)
Options IV Signal
35th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
85.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Options fairly priced (IV 35th percentile)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-8.3%)
- BULLISH: Trading 141.9% below Wall St target ($23.80)
- CAUTION: Bottoming setup, but lagging the sector by 16% over 20 days — wait for relative strength
Trading Range Analysis
30-Day Trading Range
$11.29 -
$14.94
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$1.21
(12.3%)
Support & Resistance Levels
Support Level
$9.75
Resistance Level
$13.75
Current Trend
Strong Uptrend
Technical data as of
Oct 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.66
Wall Street Target
$23.80
(+141.9%)
Revenue Growth (YoY)
-89.5%
Share & Embed Analysis
Last updated: October 24, 2026 9:26 PM ET
Data refreshes hourly during market hours. Next update: 10:26 PM
Data refreshes hourly during market hours. Next update: 10:26 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ARCT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
INSM
Insmed Inc |
STRONG BUY
24 analysts |
$197 | 53 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
22 analysts |
$109 | 64 BUY |
|
MDGL
Madrigal Pharmaceuticals… |
STRONG BUY
19 analysts |
$686 | 48 HOLD |
|
IMNM
Immunome Inc |
STRONG BUY
16 analysts |
$35 | 59 HOLD |
|
CGON
CG Oncology, Inc. Common… |
STRONG BUY
15 analysts |
$91 | 64 BUY |
